Reviva Pharmaceuticals Holdings, Inc. (RVPH)
| Market Cap | 11.26M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.86M |
| Shares Out | 12.81M |
| EPS (ttm) | -5.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 310,409 |
| Open | 0.870 |
| Previous Close | 0.884 |
| Day's Range | 0.844 - 0.900 |
| 52-Week Range | 0.590 - 23.200 |
| Beta | 0.64 |
| Analysts | Strong Buy |
| Price Target | 72.00 (+8,091.13%) |
| Earnings Date | May 14, 2026 |
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dem... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for RVPH stock is "Strong Buy." The 12-month stock price target is $72.0, which is an increase of 8,091.13% from the latest price.
News
Reviva Pharmaceuticals Holdings Transcript: Study update
Brilaroxazine is advancing to a second phase III trial for schizophrenia, with FDA feedback on a new formulation and patent extension expected mid-year. The patent strategy could extend exclusivity to 2046, enhancing value and partnership prospects. Preparations for the next trial are complete, with rapid enrollment anticipated.
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia –
What's Behind The Drop In Reviva Pharmaceuticals Stock?
According to an SEC filing from Wednesday, Reviva will sell 6,666,667 common shares priced at $1.50 each, a move that will raise more than $10 million for the company.
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Pharmaceuticals Holdings Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit
Brilaroxazine showed robust, sustained efficacy and a favorable safety profile in schizophrenia, with significant improvements in negative symptoms and low relapse rates. An additional phase 3 trial, required by the FDA, is set to begin soon, targeting NDA submission in late 2027.
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
CUPERTINO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the t...
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European...
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
CUPERTINO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings Transcript: KOL Event
Brilaroxazine demonstrated robust efficacy, safety, and adherence in late-stage trials for schizophrenia, with strong expert endorsement of its differentiated profile and potential to address key unmet needs. FDA feedback in December will determine regulatory path.
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Fall 2025 Investor Conference
The conference highlighted brilaroxazine's strong Phase 3 data in schizophrenia, with robust efficacy for negative symptoms, a favorable safety profile, and low discontinuation rates. Regulatory plans target an NDA filing in 2026, with competitive advantages over other late-stage assets.
Top 3 Health Care Stocks That May Explode In September
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that se...
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial–
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
Reviva Pharmaceuticals Holdings Transcript: Study Result
Brilaroxazine demonstrated sustained efficacy in both positive and negative symptoms of schizophrenia over 12 months, with minimal weight gain, improved metabolic and hormonal profiles, and high adherence. Biomarker data suggest neuroprotective effects, and the safety profile is favorable compared to existing antipsychotics.
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Bril...
Reviva Pharmaceuticals Holdings Transcript: Lytham Partners Spring 2025 Investor Conference
Brilaroxazine, a next-generation antipsychotic, demonstrated robust efficacy and safety in phase III trials for schizophrenia, with significant improvements in negative symptoms, neuroinflammation, and treatment adherence. NDA submission is targeted for end of 2026.
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment –
Reviva Pharmaceuticals Holdings Transcript: The Citizens JMP Life Sciences Conference 2025
Brilaroxazine showed robust efficacy and safety in phase III schizophrenia trials, with low discontinuation and strong biomarker support. The drug's unique mechanism and anti-inflammatory effects position it for expansion into other neuropsychiatric and inflammatory indications.
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical ...
Reviva Pharmaceuticals Holdings Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Brilaroxazine demonstrated robust efficacy and safety in phase 3 schizophrenia trials, with lower discontinuation rates and significant improvements in negative symptoms compared to other antipsychotics. The company plans to expand indications and expects NDA submission in Q2 2026.